Glatiramer Acetate
NDC Package 0093-6038-29

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Glatiramer Acetate is a medication used to treat multiple sclerosis (MS). Marketed by Teva Pharmaceuticals Usa, Inc., this product is identified by NDC 0093-6038 and is authorized under FDA application NDA020622.

Identification & Billing

NDC Package Code
0093-6038-29
Package Description
12 BLISTER PACK in 1 CARTON / 1 SYRINGE, GLASS in 1 BLISTER PACK (0093-6038-19) / 1 mL in 1 SYRINGE, GLASS
Product Code
0093-6038
11-Digit Billing Format
00093603829

Clinical Specifications

Proprietary Name
Glatiramer Acetate
Dosage Form
-
Usage Information
This medication is used to treat multiple sclerosis (MS). It is a protein that is thought to work by preventing your immune system from attacking the nerves in your brain and spinal cord. This effect can decrease the number of periods of disease worsening (relapses) and prevent or delay disability. It is not a cure for MS.

Regulatory & Marketing

Labeler Name
Teva Pharmaceuticals Usa, Inc.
FDA Application #
NDA020622
Marketing Category
NDA AUTHORIZED GENERIC - A product marketed as a "generic" drug under an approved New Drug Application (NDA), rather than an Abbreviated New Drug Application (ANDA),.
Start Marketing Date
04-01-2022
End Marketing Date
04-01-2022
Listing Expiration
04-01-2022
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0093-6038-29 identifies a specific commercial package of 12 blister pack in 1 carton / 1 syringe, glass in 1 blister pack (0093-6038-19) / 1 ml in 1 syringe, glass of Glatiramer Acetate, labeled by Teva Pharmaceuticals Usa, Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Teva Pharmaceuticals Usa, Inc. on April 01, 2022. The current certification is valid through April 01, 2022.

What are the primary indications for this medication?

This medication is used to treat multiple sclerosis (MS). It is a protein that is thought to work by preventing your immune system from attacking the nerves in your brain and spinal cord. This effect can decrease the number of periods of disease worsening (relapses) and prevent or delay disability. It is not a cure for MS.

How is this Teva Pharmaceuticals Usa, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00093603829. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0093-6038-29
11-Digit CMS (5-4-2)
00093-6038-29

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.